Spectral MD Reports Improved Results in Diabetic Foot Ulcer Clinical Trial

By Ed Frankl

Spectral MD Holdings Ltd. on Wednesday reported improved diagnostic accuracy in interim results from its diabetic foot ulcer clinical study.

The Texas-based analytics company said that in a clinical trial started in June 2022, its DeepView wound-imaging system, which predicts DFU size reduction within four weeks, improved by five percentage points to a diagnostic accuracy of 86% compared with its previous reported figure.

The increase in diagnostic accuracy will strengthen the company's planned 2023 submission to the U.S. Food & Drug Administration for DeepView, it said.

Shares in London rose 6.4% on the news.

The analysis was performed with an initial 100 U.S. adult subjects, Spectral said.

"We are encouraged by the interim observations from the DFU clinical study, and we look forward to completing enrollment to finalize DeepView DFU indication performance analysis and to submit for regulatory approvals," Chief Operating Officer Niko Pagoulatos said.

On Monday, Spectral said it expects its 2022 loss to be narrower than market views, on lower costs for its clinical study.

Write to Ed Frankl at [e-mail]

(END) Dow Jones Newswires

01-18-23 0427ET